Study of QLG1080 for hormone-sensitive advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, QLG1080, for patients with advanced prostate cancer that still responds to hormone therapy. It aims to see if the drug is safe and effective when combined with standard hormone treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer through a biopsy or tissue sample.
- Your cancer has spread or is advanced, and you are able to receive hormone therapy for at least 6 months.
- Your testosterone level is 150 ng/dL or higher at the screening visit.
- You are able to carry out daily activities with little to no help (ECOG score 0 or 1).
- You have not been treated with hormone therapy for prostate cancer before, or if you have, it stopped working (meaning your cancer is not hormone-resistant).
- You do not have brain metastases seen on your most recent scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests QLC5508, a new targeted drug for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The drug is designed to work in patients whose cancer has progressed despite prior hormone-based treatments.
This early-stage trial tests a new drug (QLF4113) designed to help the immune system fight metastatic castration-resistant prostate cancer—a type that has spread and stopped responding to standard hormone therapy. You may qualify if you've already tried other treatments and your overall health is stable enough for the study.
This trial tests a new drug, GLR2037, in men with metastatic prostate cancer that has spread to bones or soft tissues and is no longer responding to hormone therapy. The goal is to see if it is safe and how well it works.
This trial tests a new drug called QLH12016 combined with a hormonal therapy for men with advanced prostate cancer that has spread. It aims to see if the combination is safe and effective.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests an experimental tablet called TQB3201 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The study aims to find the right dose and see how well the drug works.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.